Market report: ASX holds firm despite global gloom
13 August, 2010 by David BinningThe Australian stock market ended slightly up today as miners helped the bourse to resist to drag of poor performers such as Telstra, although it wasn’t enough to continue the run of five consecutive weekly gains.
BioTech Capital throws in the towel
13 August, 2010 by Staff WritersBioTech Capital One, of the highest profile Australian biotech investment funds announced on Thursday that it will no longer pursue new opportunities in the sector and will liquidate its current investment portfolio, returning the proceeds to shareholders.
AQL and Farmacule merger complete
13 August, 2010 by Staff WritersThe merger of private therapeutic protein and biofuels company Farmacule and publicly-listed industrial algae specialists AquaCarotene (AQL) was completed yesterday creating a promising new Australian biotechnology company producing biofuels and plant-made compounds for use in the medical research, nutraceutical and industrial markets.
Patrys appoints Dr Marie Roskrow as new CMO and president
12 August, 2010 by Staff WritersMelbourne biotech Patrys has appointed renowned medical academic Dr Marie Roskrow as its Chief Medical Officer and President.
Cochlear reports record full year results
10 August, 2010 by Staff WritersCochlear released its full year results today reporting a 19 percent increase in net profit to $155.2 million on the back of record total revenues of $784.8 million.
Feature: Automating the personalised medicine revolution
10 August, 2010 by Fiona WylieProcessing large numbers of samples rapidly is going to be crucial if the vision of personalised medicine is ever going to become a reality.
Market report: ASX chalks up five-week winning streak
06 August, 2010 by David BinningThe Australian stock market finished the week up for the fifth week in a row today as investor’s maintained their run of confidence despite weaker-than-expected jobs and retail sales data out of the US overnight.
Study links full-fat dairy with reduced heart attack risk
05 August, 2010 by Staff WritersIn yet another case of conventional medical wisdom being turned on its head, researchers at the Queensland Institute of Medical Research (QIMR) have completed a study showing that people who consume full-fat dairy may have a lower risk of heart attack.
LCT to extend NZ diabetes trial
04 August, 2010 by David BinningXenotransplantation specialists Living Cell Technologies (LCT) announced today that promising results from a Phase II clinical trial of its cell implant Diabecell in diabetes patients in New Zealand had prompted the country’s health regulator to approve the addition of four more patients.
Patrys to start clinical trials on melanoma patients
02 August, 2010 by Staff WritersMelbounre biotech Patrys announced today that the Royal Adelaide Hospital has approved a clinical trial evaluating its PAT-SM6 natural human antibody as a treatment for melanoma.
Market report: ASX down as local results disappoint
30 July, 2010 by David BinningThe Australian stock market was down for the second day in a row today although it ended the month on a four-week winning streak.
Halcygen (ASX:HGN) to expand board following departure of director and COO
30 July, 2010 by Tim DeanMelbourne-based generic pharmaceutical manufacturer, Halcygen Pharmaceuticals (ASX:HGN), is seeking to add new talent to its board and senior management following the departure of Executive Director and COO, Craig Bottomley yesterday.
Patrys adds to antibody portfolio
29 July, 2010 by Staff WritersHuman antibody therapy specialists Patrys announced today that is has acquired a new anti-cancer antibody which has been shown to significantly reduce gastric and pancreatic tumours in animal models of human cancers.
Hurdles remain for Botox as a migraine treatment
28 July, 2010 by David BinningBotox was approved in the UK this month for the treatment of migraines, however, the high costs of the cosmetic treatment as well as lingering safety concerns may restrict its ability to penetrate this new market.
Biota Holdings targeting asthma market with anti-viral drug
27 July, 2010 by Staff WritersBiota Holdings today commenced a 400-member trial in the US of its anti-viral drug BTA798 on sufferers of asthma who present with cold symptoms.
